Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Debt Issuance
confidence 75%
filed 2026-08-28
Item 8.01
OFS Capital is exercising a redemption option on $20 million of its 7.50% Notes due 2028, with redemption at par plus accrued interest on September 29, 2026. While this is technically a debt reduction rather than issuance, the taxonomy's debt_issuance category encompasses "creation of a new direct financial obligation" and "entry into or amendment of a credit facility." A partial redemption represents a material modification of the company's debt structure and capital position. However, this is closer to a debt retirement than a new obligation, so confidence is moderate; the event is material to investors assessing the company's leverage and liquidity.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-28
Netcapital received a delinquency notification from Nasdaq on August 24, 2026 for failure to timely file its Form 10-K for fiscal year ended April 30, 2026, placing it in violation of Nasdaq Listing Rule 5250(c)(1). The company has 60 days to submit a compliance plan and faces potential delisting if it cannot regain compliance. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Operational Other
confidence 65%
filed 2026-08-28
Item 1.01
The 8-K discloses a Product Purchase Agreement dated August 25, 2026, between Boxabl Inc. and LC Vegas Acquisitions, LLC, with a First Amendment also executed the same date. While Item 9.01 exhibits are shown, the Item 1.01 reference suggests this involves a material transaction or contract. The redaction of portions under Reg S-K 601(b)(10) indicates confidential commercial terms. This appears to be a material commercial contract or product sale arrangement, which qualifies as an operational event, though the specific nature (whether a one-time sale, ongoing supply arrangement, or other transaction) cannot be fully determined from the exhibits section alone.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-08-28
The filing discloses the Company's quarterly determination of net asset value (NAV) and NAV per Class A unit as of June 30, 2026, including a detailed breakdown of assets ($761.5M), liabilities ($306.5M), resulting NAV ($455.0M), and NAV per unit ($116.37). This is a material financial disclosure for a real estate investment company, as NAV is the primary valuation metric for unitholders and directly affects investor assessment of the registrant's financial position and unit value.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-28
EX-99.1
This is a press release announcing FinVolution Group's unaudited financial results for the second quarter ended June 30, 2026. The exhibit discloses comprehensive quarterly financial metrics including net revenue (RMB3,403.2 million), net profit (RMB426.8 million), operating profit, and segment performance, along with management commentary on business outlook. This is a classic earnings release event disclosing material quarterly results.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-28
The filing discloses FingerMotion's strategic pivot to become an owner-operator of behind-the-meter AI data center capacity in North America, executed through a partnership with BlueFlare Energy Solutions and a 9.9% equity investment in Lyken.AI (closed August 17, 2026). This represents a material operational and strategic business transformation from the company's existing mobile payment and telecommunications operations in China. While the filing also mentions the Lyken.AI acquisition, the primary focus is the strategic business plan and operational repositioning rather than the acquisition itself as a discrete M&A event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-28
The filing discloses an "Any Market Purchase Agreement" with Alumni Capital LP under which INVO Fertility has sold 2,094,395 shares of common stock for approximately $3.591 million at an average price of $1.71 per share, with the right to sell up to $15 million (potentially $50 million) more. This is a classic dilutive equity issuance arrangement. While Item 7.01 covers an investor presentation and Item 8.01 frames this as "Other Events," the substantive disclosure is of an ongoing private placement of common stock, which materially dilutes existing shareholders and is a key capital-raising mechanism for small-cap companies.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 89%
filed 2026-08-28
EX-99.1
Antelope Enterprise Holdings Ltd. completed a private placement on August 24, 2026, issuing Class A ordinary shares and common share purchase warrants (exercisable 2026–2030) to investors in reliance on Section 4(2) of the Securities Act. The combined equity and warrant issuance represents a material capital raise and dilution to existing shareholders.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-28
EX-99.1
This is a press release announcing Core AI Holdings' financial results for Q2 and six months ended June 30, 2026. The exhibit discloses quarterly revenue of $22.4 million (56% YoY growth), gross loss improvement to $11,000 (97% reduction), net loss of $1.6 million, and operating cash flow of $5.5 million for the six-month period. These are discrete quarterly financial results presented as a results announcement, not a periodic financial report filing itself. The disclosure is material as it reports significant revenue growth and operational improvements that would affect investor assessment.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-08-28
EX-99.1
Lucas GC Ltd implemented a 125-for-1 share consolidation effective September 1, 2026, pursuant to shareholder approval on December 5, 2025. The consolidation affects share price, trading mechanics (new CUSIP), and shareholder percentage interests, though it does not alter economic ownership.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-28
EX-99.1
This is a Securities Purchase Agreement dated August 25, 2026, under which Magic Empire Global Limited is issuing and selling Class A ordinary shares for an aggregate purchase price of US$6,720,000 to non-U.S. persons under Regulation S. The agreement specifies issuance of shares at US$0.168 per share (15% of the prior trading day's closing price), representing a private placement of equity securities. This constitutes a dilutive issuance of unregistered equity securities to raise capital, which is material to investors' assessment of ownership dilution and capital structure.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 92%
filed 2026-08-28
The filing discloses a 1-for-8 reverse stock split implemented on August 28, 2026, explicitly stated to be "intended to, among other things, assist the Company in maintaining compliance with the minimum bid price requirement for continued listing on The Nasdaq Global Market." This language signals that the company faced delisting risk due to failure to meet Nasdaq's minimum bid price rule, making the reverse split a remedial action to preserve listing status.
View raw filing on EDGAR →
6-K
M&A activity
confidence 92%
filed 2026-08-28
EX-99.1
The exhibit discloses pro forma financial statements reflecting a disposal transaction: on August 28, 2026, the Company entered into a sale and purchase agreement to sell its wholly owned subsidiary Swift Top Capital Resources Limited for US$1.00 to Mrs. Un Son I. This constitutes a material disposition requiring pro forma presentation under Regulation S-X Article 11. The exhibit also discloses a subsequent private placement of 12.3 million units at US$0.20 per unit generating approximately US$1.84 million in net proceeds, which is a dilutive equity issuance. The primary event is the disposal/disposition of a subsidiary.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-28
Item 3.01 discloses that Nasdaq has determined to delist Jupiter Neurosciences' common stock from The Nasdaq Capital Market because the market value of listed securities fell below the $35 million minimum required under Listing Rule 5550(b)(2) for 30 consecutive trading days, and the Company failed to regain compliance within the 180-day cure period ending August 25, 2026. While the Company intends to appeal, the delisting determination is final and material to investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
BranchOut Food Inc. entered into an underwriting agreement on August 26, 2026, to issue 820,588 shares of common stock at $3.40 per share, with gross proceeds of approximately $2.79 million and net proceeds of approximately $2.50 million after underwriting discounts and expenses. This is a registered public offering of equity securities that closed on August 28, 2026, disclosed under Item 1.01 (Entry into a Material Definitive Agreement). The offering is material to investors as it represents a significant dilution to existing shareholders and a material capital raise for the company.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-08-28
Item 7.01
The filing discloses execution of a definitive merger agreement between Volato Group, Inc. and Alignment Engine, Inc., valued at approximately $500 million. The press release (Exhibit 99.1) explicitly states "Volato Group Signs Definitive Agreement for $500 Million AI Infrastructure Merger with Alignment Engine" and describes this as a transaction that "repositions Volato around advanced AI infrastructure." This is a material acquisition/merger transaction that would substantially affect the registrant's business and is clearly reportable under Item 1.01 or 2.01 of Form 8-K, even though disclosed via Item 7.01 (Regulation FD Disclosure).
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-28
My Size, Inc. received a notice from Nasdaq on August 25, 2026 that its stockholders' equity of $2,347,000 as of June 30, 2026 falls below the minimum $2,500,000 requirement under Nasdaq Listing Rule 5550(b)(1). The company has 45 days to submit a compliance plan and faces potential delisting if it cannot regain compliance within any extension period granted. This is a clear delisting risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-08-28
The filing discloses a promotion of Rebecca A. Jennings from Senior Vice President to Executive Vice President, coupled with material compensation amendments including base salary increase to $450,000, enhanced bonus targets (80% of base), improved severance multiples (1.5x to 2x base salary), and a special RSU grant valued at $239,500. While the filing involves both an appointment and compensation changes, the central focus is the compensatory arrangement amendment approved by the Compensation Committee, making exec_compensation the most salient classification.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-08-28
Eastern International Ltd. entered into a Securities Purchase Agreement on August 27, 2026, to issue 200,000 Series B Preferred Shares to Chairman and CEO Albert Wong at US$1.00 per share (US$200,000 aggregate). The shares carry 100 votes each and are convertible into ordinary shares, representing a dilutive equity issuance to an insider. This is a material capital event affecting ownership structure and voting rights.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-28
Shuttle Pharmaceuticals received a notification letter from Nasdaq on August 28, 2026, indicating noncompliance with Nasdaq Listing Rule 5250(c)(1) due to delayed filing of its Form 10-Q for the period ended June 30, 2026. The company has 60 days to submit a compliance plan and up to 180 days to regain compliance, with explicit warning that failure to do so will result in delisting from Nasdaq. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Legal Other
confidence 85%
filed 2026-08-28
KonaTel discloses that its 51%-owned subsidiary IM Telecom received an FCC Notice on July 27, 2026, alleging violations of the Lifeline Advantage Program rules, including improper subscriber enrollment, unapproved transfer of control, and due process violations. IM Telecom filed a response on August 25, 2026, contesting the allegations. The filing explicitly states "No assurance can be given that the FCC's noticed action regarding IM Telecom may not result in adverse consequences to KonaTel," indicating material regulatory risk to the parent company. This is a regulatory investigation and enforcement action that does not fit the specific litigation or covenant-breach categories but is clearly a material legal/regulatory event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 85%
filed 2026-08-28
The filing's primary disclosure is Item 5.07, which reports the results of SharonAI's August 27, 2026 Annual Meeting of Stockholders. The filing details voting outcomes for four proposals: ratification of HoganTaylor LLP as auditor, election of two Class I directors (Alastair Cairns and Benjamin Adams), approval of the Second Amendment to the 2025 Omnibus Equity Incentive Plan, and approval of pre-funded warrant issuance under Nasdaq Rule 5635(b). While Item 5.02 also appears, it merely cross-references the equity plan amendment already approved by vote. The substantive event is the shareholder vote and its results.
View raw filing on EDGAR →
6-K
Other material
confidence 65%
filed 2026-08-28
EX-99.1
The Company discloses unusual trading activity in its ordinary shares on NYSE American on August 12 and August 27, 2026, and states it has been unable to determine whether corrective actions are appropriate or identify any material business development to account for the activity. This disclosure is made pursuant to Section 401(d) of the NYSE American Company Guide. While the Company explicitly denies knowledge of any material development, the unusual market action itself and the Company's inability to explain it represents a material disclosure that would affect a reasonable investor's assessment of the stock and the Company's circumstances.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-28
The filing discloses issuance of convertible promissory notes totaling $165,000 principal ($150,000 consideration) that will convert into common stock at maturity (November 26, 2026) at a price of the lower of 80% of VWAP or $1.00 per share. This is a dilutive financing instrument. While Item 1.01 addresses the debt issuance itself, the convertible feature and the Company's agreement to use net proceeds from a concurrent Common Stock Purchase Agreement to repay the notes creates a dilutive capital structure typical of distressed small-cap financings. The 1% monthly interest rate and short maturity also signal financial stress. Item 5.02 separately discloses a board appointment (Lewis Wilks), but the principal material event is the dilutive convertible issuance.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 72%
filed 2026-08-28
The 6-K furnishes Amendment No. 1 to a Sales Agreement with A.G.P./Alliance Global Partners dated August 28, 2026, which amends an original sales agreement from February 28, 2025. Sales agreements with investment banks are typically used to establish at-the-market (ATM) equity offering programs or debt issuance facilities. The amendment to such an agreement, incorporated by reference into an F-3 registration statement, signals a material capital-raising activity. While the body does not explicitly state the nature of the securities, the structure and timing suggest a debt or equity issuance facility amendment.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
SRX Global Inc. entered into a Securities Purchase Agreement on August 27, 2026, selling 3,579 shares of Series C convertible preferred stock for $2,862,500 in a private placement to accredited investors. The Series C Preferred Stock is convertible into common stock at a fixed conversion price of $2.1888 per share, with alternate conversion mechanisms triggered by specified events. The filing explicitly discloses this under Item 3.02 (Unregistered Sales of Equity Securities) and Item 1.01 (Entry into a Material Definitive Agreement), and notes reliance on Section 4(a)(2) and Regulation D exemptions. This is a classic dilutive private placement raising capital through convertible securities.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-28
On August 26, 2026, Oragenics received a deficiency notice from NYSE American stating the company is not in compliance with continued listing standards (Sections 1003(a)(ii) and 1003(a)(iii)) due to stockholders' equity of $3.7 million falling below the $6 million threshold required for companies with net losses in five consecutive fiscal years. The company has until February 25, 2028 to regain compliance or face delisting procedures, with the stock now trading under the ".BC" (below compliance) designation.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-28
AiRWA Inc. received a deficiency notification from Nasdaq on August 24, 2026, for failure to timely file its Annual Report on Form 10-K, violating Nasdaq Listing Rule 5250(c)(1). The company has 60 days to submit a compliance plan and up to 180 days to regain compliance, with no assurance of success. This is a classic delisting-risk disclosure under Item 3.01, materially threatening the company's continued listing on Nasdaq Capital Market.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-08-28
The filing discloses a 1-for-15 reverse stock split of Glucotrack's common stock, approved by stockholders on August 18, 2026 and effective August 28, 2026 (Item 5.03). This is a governance/capital structure event that materially affects share count and per-share metrics. While reverse splits can signal financial distress, the disclosure itself is a routine corporate action and does not indicate going concern issues or other terminal events. The accompanying Item 8.01 tables merely restate historical financial metrics on a post-split basis for comparability.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-28
The filing discloses multiple unregistered equity issuances under Item 3.02: a $1.2M convertible note convertible into Class A Common Stock, Series A Preferred Stock convertible into Class A Common Stock, a warrant to purchase additional Preferred Stock, and 834,782 Extension Shares of Class A Common Stock issued to Kips Bay Select, LP. These are private placements with dilutive conversion features, though the filing also includes governance changes (Class B conversion and director departures under Item 3.03 and 5.02) and debt issuance (Item 2.03). The most salient material event is the dilutive equity issuance structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-28
VivoPower announced two unregistered equity issuances totaling approximately $16.3 million: (1) 1.2 million Class A ordinary shares to Prince Abdulaziz bin Turki bin Talal Al Saud at $6.05/share ($7.3M), and (2) $9M+ of Class A ordinary shares to UK/EU institutional investors at $4.20/share, both undertaken as direct placements in reliance on Regulation S and not registered under the Securities Act. These are classic dilutive private placements that would materially affect shareholder ownership and capital structure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-28
The filing discloses the issuance of 15,138 shares of common stock to BEN Capital Fund I, LLC upon cash exercise of previously issued warrants, generating $259,125.60 in proceeds. The shares are restricted securities issued pursuant to Section 4(a)(2) of the Securities Act and Regulation D, indicating an unregistered equity issuance. This represents a dilutive capital raise typical of warrant exercises by private investors, material to shareholders' ownership interests.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-08-28
Item 5.02
The filing discloses both the departure of CFO Julia Brau Donnelly (effective October 30, 2026) and the appointment of Vikram Naidu as Principal Financial Officer on an interim basis (effective the same date). While both events are disclosed, the principal forward-looking action is the appointment of Naidu to the CFO role, making this an exec_appointment. The departure is contextual background explaining why the appointment is necessary. This is material because it involves a change in the Company's chief financial officer, a key executive position affecting investor confidence and financial oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-08-28
Item 5.02
Peter Owino was appointed Chief Accounting Officer effective September 1, 2026, following his service as Interim Chief Accounting Officer. The appointment includes a base salary of $350,000, bonus targets, 100,000 restricted stock awards as inducement equity, and severance provisions.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-08-28
Item 3.01
The filing discloses that the Nasdaq Listing Council has affirmed a determination to delist BioAtla's common stock from Nasdaq effective August 31, 2026, due to non-compliance with the $1.00 bid price requirement and $2.5 million stockholders' equity requirement. The Company expects trading suspension on Nasdaq and transfer to OTC Markets, which the filing acknowledges "may have a material adverse effect on the trading price and volume for the Common Stock." This is a definitive delisting notice, not merely a risk or warning.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-28
Item 8.01
The filing discloses the issuance and closing of commercial mortgage pass-through certificates totaling approximately $687 million in aggregate principal ($528.97 million publicly offered and $158 million privately offered) on August 28, 2026. This represents the creation of new direct financial obligations secured by 30 commercial mortgage loans, structured as a securitization trust. The disclosure details the underwriting, pricing, and credit risk retention requirements, which are hallmarks of a material debt issuance event.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 92%
filed 2026-08-28
EX-99.1
The exhibit discloses that Trinity Biotech received a Nasdaq staff determination letter on August 28, 2026, notifying the company that it failed to regain compliance with the market value of publicly held shares (MVPHS) requirement of $15 million by the August 18, 2026 deadline. The company's securities are now subject to suspension/delisting unless it requests and obtains a hearing before a Nasdaq Hearings Panel. This is a material delisting risk disclosure under Item 3.01 equivalent, as the company faces imminent delisting absent successful remediation or panel extension.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-08-28
Item 8.01
The Board of Directors declared a cash dividend of $0.37 per share payable on October 23, 2026 to stockholders of record on October 9, 2026. This is a straightforward dividend declaration disclosed via press release, and the company states its intent to continue paying dividends on a quarterly basis. Dividend declarations are material capital allocation events affecting shareholder returns.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-28
Item 8.01
The filing discloses pro forma financial information for Malibu Boats' acquisition of Saxdor Yachts Oy, consummated on March 2, 2026, for approximately $203.9 million in aggregate consideration (cash, stock, and earnout). This is a material acquisition requiring pro forma disclosure under Regulation S-X Article 11, representing a significant business combination that would materially affect investor assessment of the registrant.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-08-28
Item 8.01
The filing discloses a 1-for-8 reverse stock split announced on August 26, 2026, along with operational and financial updates including margin expansion (6.1% to 29.1%), a $54.6M HHS contract award, debt reduction, and multi-year revenue visibility. While the reverse split itself is a capital structure event, the press release centers on operational and strategic achievements (acquisitions, margin improvement, contracted revenue) rather than a discrete financial obligation or governance action. This is best classified as an operational/strategic disclosure that does not fit the specific categories of debt issuance, dividend distribution, or other named types.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-28
Item 2.03
Lucid Group drew $400 million on a Delayed Draw Term Loan facility from Ayar Third Investment Company (PIF affiliate), increasing total outstanding principal to $1.7 billion under the existing credit facility.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 80%
filed 2026-08-28
Item 5.02
Lucid appointed three senior executives: Shawn Mirabal as President of North America Commercial, Mike Molino as Vice President of Finance, and Angela Zepeda as Vice President, Global Marketing, to strengthen commercial execution, financial discipline, and customer engagement.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 89%
filed 2026-08-28
Item 1.01
Boeing entered into a new $3.0 billion, 364-day revolving credit agreement with Citibank and JPMorgan on August 24, 2026, and amended two existing five-year credit agreements ($4.0 billion and $3.0 billion) to extend their terms and add liquidity maintenance covenants, creating or materially modifying direct financial obligations totaling approximately $10 billion in commitments.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-08-28
Item 5.02
Ray Pittard was elected to the Board of Directors on August 25, 2026, to fill a vacancy created by the Board's expansion from twelve to thirteen directors.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-08-28
Item 5.02
The disclosure centers on the adoption of a new Severance Plan effective August 27, 2026, and the designation of four named executive officers (CEO Jonathan Neman, Chief Concept Officer Nicolas Jammet, CFO Jamie McConnell, and COO Jason Cochran) as Tier I or Tier II Participants with specified severance benefits. This is a compensatory arrangement for officers that materially affects their employment terms and potential payouts upon termination or change of control, making it a core exec_compensation event rather than a departure or appointment.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-28
EX-99.1
This press release announces NMPA (China National Medical Products Administration) conditional approval of ATLED® (fanregratinib) for treating FGFR2-altered intrahepatic cholangiocarcinoma. This is a material regulatory milestone and product approval event that does not fit the specific `earnings_release` category (no financial results disclosed) nor other named event types. The approval represents a significant operational and commercial achievement for the company's drug development pipeline, supported by Phase II trial data meeting primary endpoints (42.5% ORR). This would materially affect a reasonable investor's assessment of the company's commercial prospects and pipeline value.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-08-28
HSBC Holdings plc issued CNY2.5 billion in 1.950% Fixed Rate Notes due 2030 and CNY1.5 billion in 2.300% Fixed Rate Notes due 2034 under its Debt Issuance Programme on 28 August 2026, with admission to trading on the London Stock Exchange Main Market. This is a material creation of direct financial obligations totaling approximately CNY4 billion in new debt.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-28
Item 5.07
PEDEVCO held its Annual Meeting of stockholders on August 27, 2026, with voting results on six director elections, auditor ratification, executive compensation advisory votes, say-on-pay frequency, and equity plan amendment approval. All six director nominees were elected and all major proposals passed.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-08-28
Item 5.02
Stockholders approved the Third Amendment to the 2021 Equity Incentive Plan, which materially increased the aggregate shares available for issuance from 900,000 to 1,800,000 shares and increased the maximum awards per recipient. The amendment became effective upon stockholder approval on August 27, 2026.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-28
Item 1.01
Hertz issued two series of asset-backed notes totaling approximately $834.75 million (Series 2026-3 for $357.75M and Series 2026-4 for $477M) through special-purpose subsidiary HVF III on August 27, 2026, secured by rental car fleet assets. The proceeds were used to refinance existing variable funding notes and finance vehicle acquisitions.
View raw filing on EDGAR →